Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cinnamic, phenylpropiolic and phenylpropanoic acid derivatives useful as anti-tumour agents

一种化合物、芳基的技术，应用在肉桂酸和苯丙炔酸和苯丙酸衍生物领域，能够解决抗肿瘤治疗无效等问题

Inactive Publication Date: 2008-06-04
SIGMA TAU IND FARMACEUTICHE RIUNITE SPA
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Regardless of the cause of resistance, antineoplastic therapy is ineffective when used long-term

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cinnamic, phenylpropiolic and phenylpropanoic acid derivatives useful as anti-tumour agents
  • Cinnamic, phenylpropiolic and phenylpropanoic acid derivatives useful as anti-tumour agents
  • Cinnamic, phenylpropiolic and phenylpropanoic acid derivatives useful as anti-tumour agents

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0173] Preparation of (2E)-N-hydroxy-3-(4-{[(allyloxy)imino]methyl}phenyl)acrylamide (ST2984)

[0174] Step 1: Warm trans-4-formyl-cinnamic acid A (Y=CH=CH, R 1 = H, R 3 =H, 0.346 g, 1.96 mmol.) and B O-allylhydroxylamine hydrochloride (0.258 g, 2.37 mmol.) were dissolved in 2 mL of DMF and stirred for 5 h. Then, the solution was diluted with AcOEt and washed with water. in Na 2 SO 4 The organic layer was dried and then concentrated under reduced pressure to give 0.421 g of intermediate C(2E)-3-(4-{[(benzyloxy)imino]methyl}phenyl)acrylic acid (93% yield) .

[0175] MS (ESI) m / z: [M-1] - =230.3

[0176] Step 2: Intermediate C from Step 1 (0.123 g, 0.53 mmol) was dissolved in 1.5 mL DMF along with HATU (0.222 g, 0.58 mmol) and DIEA (185 μL, 1.06 mmol) in a flask. After 0.5 h, a solution of hydroxylamine hydrochloride (0.055 g, 0.80 mmol) and DIEA (139 μL, 0.80 mmol) in 1.5 mL DMF was added. The mixture was stirred at room temperature for 24 h, then diluted with HCl solu...

Embodiment 2

[0182] Preparation of (2E)-N-hydroxy-3-{4-[(phenoxyimino)methyl]phenyl}acrylamide (ST2985)

[0183] Step 1: Starting from trans 4-formyl-cinnamic acid A (0.342 g, 1.94 mmol) and B 0-phenylhydroxylamine hydrochloride (0.339 g, 2.33 mmol) as described in Example 1, Step 1, gave Intermediate C(2E)-3-{4-[(phenoxyimino)methyl]phenyl}acrylic acid used in the synthesis of ST2985 (0.520 g, 99% yield).

[0184] MS (ESI) m / z: [M-1] - =266.4

[0185] Step 2: Compound ST2985 (0.100 g, 48% yield) was obtained starting from Intermediate C (0.201 g, 0.75 mmol) as described in Example 1, Step 2.

[0186] MS(ESI)m / z: [M-1] - =281.1

[0187] [M+23] + =305.0

[0188] 1 H-NMR (200MHz, DMSO-d6) δ (ppm): 6.5-6.7 (d, J = 15.7Hz, 1H, CH), 7.0-7.1 (t, J = 6.9Hz, 1H, CH ar ), 7.2-7.3 (d, J=8.0Hz, 2H, 2×CH ar ), 7.3-7.4 (t, J=7.3Hz, 2H, 2×CH ar ), 7.4-7.6 (d, J=16.1Hz, 1H, CH), 7.6-7.7 (d, J=7.7Hz, 2H, 2×CH ar ), 7.8-7.9 (d, J=7.7Hz, 2H, 2×CH ar ), 8.7 (s, 1H, CH), 9.1 (...

Embodiment 3

[0191] Preparation of (2E)-N-hydroxy-3-[4-({[(4-nitrobenzyl)oxy]imino}-methyl)phenyl]acrylamide (ST2987)

[0192] Step 1: As described in step 1 of Example 1, from trans-4-formyl-cinnamic acid A (0.348g, 1.97mmol) and B 0-(4-nitrobenzyl) hydroxylamine hydrochloride (0.485g, 2.37 mmol) to give intermediate C(2E)-3-[4-({[(4-nitrobenzyl)oxy]imino}-methyl)phenyl]acrylic acid (ST3075) for the synthesis of ST2987 (0.610 g, 94% yield).

[0193] MS(ESI)m / z: [M-1] - =325.3

[0194] 1 H-NMR (200MHz, DMSO-d6) δ (ppm): 5.34 (s, 2H, CH 2 ), 6.5-6.7 (d, J=15.7Hz, 1H, CH), 7.5-7.8 (m, 7H, 6×CH ar , CH), 8.2-8.3 (d, J=8.4Hz, 2H, 2×CH ar ), 8.41(s, 1H, CH), 12.4(bs, 1H, OH).

[0195] 13 C-NMR (50MHz, DMSO-d6, δ): 75.0, 121.0, 124.3, 128.1, 129.4, 129.5, 133.8, 136.7, 143.7, 146.5, 147.7, 150.3, 168.2.

[0196] Step 2: Compound ST2987 (0.120 g, 44% yield) was obtained starting from Intermediate C (0.262 g, 0.80 mmol) as described in Example 1, Step 2.

[0197] MS(ESI)m / z: [M-1] - =34...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Cinnamic and phenylpropiolic acid derivatives of Formula (I) having antitumour and chemosensitizing activity are described. Also described are pharmaceutical compositions containing the above-mentioned compounds, for the treatment of tumours.

Description

field of invention [0001] The present invention relates to cinnamic acid and phenylpropiolic acid and phenylpropionic acid derivatives having antitumor activity. Background of the invention [0002] Currently, tumor treatment is achieved through surgical intervention, radiation therapy, and chemotherapy. The latter disadvantage is mainly due to the toxicity of cytotoxic drugs (which is usually not restricted to cancer cells) and the acquired resistance of cancer cells to some of the most widely used drugs (which reduces the long-term efficacy of the treatment). [0003] Surgical elimination of the primary tumor is not always possible and in no case prevents the most metastatic tumors, such as breast cancer or melanoma, from invading other target organs. [0004] Treatment of metastatic tumors has proven unlikely to completely cure patients; therefore, cytotoxic drug therapy is now considered palliative and life-prolonging rather than curative. Chronic treatment with drugs ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07C251/48C07C251/80C07D209/08A61P35/00A61K31/165A61K31/195A61K31/405
CPCC07C251/40C07C251/52C07C313/28C07C251/60C07D295/088C07D209/08C07C381/00C07C251/48C07C251/86C07C251/36A61P35/00A61P35/02A61P35/04A61P43/00A61K31/165A61K31/195A61K45/06A61K2300/00
Inventor C·皮萨诺G·巴蒂斯图齐M·迪马尔佐G·詹尼尼M·马尔齐L·韦希F·祖尼诺R·佩齐
Owner SIGMA TAU IND FARMACEUTICHE RIUNITE SPA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com